AI Terminal
Pharmanutra
Report Publication Announcement • Dec 21, 2023
4324_rns_2023-12-21_36858543-c517-4898-9e7e-800425efee51.pdf
Report Publication Announcement
Open in ViewerOpens in native device viewer
| Informazione Regolamentata n. 20106-51 |
Data/Ora Inizio Diffusione 21 Dicembre 2023 15:24:35 |
Euronext Star Milan | |
|---|---|---|---|
| Societa' | : | PHARMANUTRA | |
| Identificativo Informazione Regolamentata |
: | 184725 | |
| Nome utilizzatore | : | Roberto Lacorte | |
| Tipologia | : | REGEM | |
| Data/Ora Ricezione | : | 21 Dicembre 2023 15:24:35 | |
| Data/Ora Inizio Diffusione | : | 21 Dicembre 2023 15:24:35 | |
| Oggetto | : | PR Financial Calendar 2024 | |
| Testo del comunicato |
Vedi allegato
PHARMANUTRA S.P.A.: PUBLICATION OF THE 2024 CORPORATE EVENTS CALENDAR
Pisa, 21st December 2023 - PharmaNutra S.p.A. (the "Company") announces the dates for the approval of the financial results of the Company by the Board of Directors and the Shareholders' Meeting:
| Date | Event |
|---|---|
| March 15th, 2024 | Board of Directors for the approval of the Financial Statements as of 31st December 2023 |
| th, 2024 | Ordinary Shareholders' Meeting for the approval of the Financial |
| April 16 | Statements as of 31st December 2023 |
| th, 2024 | Board of Directors Meeting for the approval of the Interim Management |
| May 13 | Statements as of 31st March 2024 |
| th, 2024 | Board of Directors Meeting for the approval of the Half-Yearly Report as |
| September 9 | of 30th June 2024 |
| November 11th, 2024 | Board of Directors Meeting for the approval of the Interim Management Statements as of 30th September 2024 |
Any amendments to the above calendar will be notified to the market timely.
PharmaNutra S.p.A.
PharmaNutra S.p.A.
Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. PharmaNutra is a leader in the production of iron-based nutritional supplements with the SiderAL® brand, where it can claim important Sucrosomial® Technology patents, and is considered one of the top players in the sector of medical devices dedicated to the restoration of joint capacity thanks to the Cetilar® brand, now on the market also with Cetilar® Nutrition, a line of supplements designed for those who practice sport constantly. Over the years the Group - present abroad in 85 countries - has developed precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence. PharmaNutra.it
For further information:
Via Delle Lenze, 216/b - 56122 Pisa Tel. +39 050 7846500 [email protected]
Internal Press Office [email protected]
PharmaNutra S.p.A. Press Office - Spriano Communication & Partners
Via Santa Radegonda, 16 - 20121 Milan Tel. +39 02 83635708
Matteo Russo [email protected] Cristina Tronconi [email protected]
PharmaNutra S.p.A.
Sede Legale Via Campodavela, 1 - 56122 Pisa | +39 050 7846500 pharmanutra.it | [email protected] | [email protected] C.F. / P.Iva / Reg. Impr. 01679440501 - Codice SDI SUBM70N Cap.Soc. € 1.123.097,70 I.V. | REA 146259
